This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wolf Haldenstein Announces Investigation Of Sarepta Therapeutics, Inc.,

Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the securities of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) between July 24, 2013 and November 12, 2013.

The complaint alleges that during the Class Period, certain of the Company’s officers and directors violated federal securities laws by making false and misleading statements concerning the Company’s lead therapeutic candidate for the treatment of Duchenne muscular dystrophy, eteplirsen.

Specifically, the Complaint alleges that multiple misleading statements were made concerning: (1) the prospects of the Food and Drug Administration's ("FDA") acceptance for consideration of a New Drug Application ("NDA") for eteplirsen based on Sarepta's Phase IIb study data set, and (2) the significance of the Phase IIb data set.

On November 12, 2013, Sarepta disclosed that the FDA informed the Company that its announced NDA filing for eteplirsen was premature. On this news, Sarepta's stock price collapsed from its closing price of $36.56 per share on November 11, 2013 to $13.16 per share on November 12, 2013.

If you purchased Sarepta common stock during the Class Period, you may, no later than March 28, 2014, request that the Court appoint you as lead plaintiff of the class.

If you are a shareholder of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) with a loss of $75,000 or more and would like additional information concerning your rights in this matter, please contact us at:

Gregory M. Nespole or Patrick DonovanWolf Haldenstein Adler Freeman & Herz LLP270 Madison AvenueNew York, New York 10016

Phone Numbers:(800) 575-0735(212) 545-4600

Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm.

Wolf Haldenstein did not file the original complaint against Sarepta Therapeutics, Inc.

Email:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,630.27 +189.68 1.09%
S&P 500 2,093.25 +25.61 1.24%
NASDAQ 5,089.2060 +49.43 0.98%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs